Resolution Therapeutics Announces £63.5 Million Series B …

Oct 3, 2024 · Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the …

CouponFollow Extension

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

2 days from now

Oct 3, 2024 · Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the …

yahoo.com

$76
OFF

Resolution Therapeutics Scores £63.5 Million In Series B Round

2 days from now

Oct 3, 2024 · UK-based biotech Resolution Therapeutics has raised £63.5 million ($76.8 million) in a series B round led by Syncona to advance its macrophage therapy, RTX001, into clinical …

thepharmaletter.com

£64
OFF

Resolution’s £64M Series B To Advance Macrophage Cell Therapy

2 days from now

Oct 3, 2024 · A preview of the next edition of BioWorld, Oct. 3, 2024. Resolution Therapeutics Ltd. is preparing for a phase I/II trial of its autologous engineered macrophage cell therapy, RTX …

bioworld.com

$83
OFF

Resolution Scores $83m To Develop Macrophage Cell Therapies

2 days from now

Oct 3, 2024 · Resolution Therapeutics has raised £63.5m ($83.3m) in a Series B financing round to develop its macrophage cell therapies. The UK-based company plans to use the money to …

pharmaceutical-technology.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

2 days from now

Mar 10, 2024 · Edinburgh and London, UK, 3 October 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company focused on unlocking the …

synconaltd.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

2 days from now

Oct 3, 2024 · Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory …

prnewswire.com

$83
OFF

Resolution Therapeutics Secures $83M To Advance Liver Therapy

2 days from now

Oct 3, 2024 · Resolution Therapeutics was co-founded by Syncona, a UK-based investment trust focused on helping to found, fund and progress healthcare companies, in 2020 after a two …

biopharma-reporter.com

£26
OFF

Resolution Therapeutics Announces A £26.6m Series A ... - Syncona

2 days from now

May 6, 2024 · Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases characterised by life-threatening …

synconaltd.com

£10
OFF

Resolution Therapeutics Announces A £10m Extended Series A

2 days from now

London, 5 April, 2022 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat advanced liver disease, today …

synconaltd.com

FAQs about Resolution Therapeutics Announces £63.5 Million Series B … Coupon?

What is resolution Therapeutics?

About Resolution Therapeutics Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases. ...

Is resolution a regenerative biopharmaceutical company?

EDINBURGH, Scotland and LONDON, Oct. 3, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases, today announces it has raised £63.5 million in Series B financing. ...

Who founded resolution Therapeutics?

In 2020, Professor Forbes co-founded Resolution Therapeutics, a biotech company focused on engineering macrophage cell therapies to deliver a more effective and durable treatment for patients with end-stage liver disease. ...

Who is resolution Therapeutics VP of research operations?

Lara is the VP of Research Operations and a member of the founding team at Resolution Therapeutics. She achieved a Bachelor degree in Medical and Pharmaceutical Biotechnology, followed by a Master in Cellular and Molecular Medical Biotechnology from the San Raffaele University in Milan, Italy. ...

Will rtx001 measure clinical events?

The first-in-human study of RTX001 will measure clinical events as the primary efficacy endpoint. Resolution Therapeutics spun out from the University of Edinburgh in 2020. Credit: Gorodenkoff / Shutterstock.com. ...

When did resolution Therapeutics get MHRA approval?

Resolution Therapeutics approval from the MHRA follows the presentation of key proof of concept data by the University of Edinburgh at the European Association for the Study of the Liver (EASL) Congress 2024 which took place from 5 to 8 June in Milan, Italy. Resolution Therapeutics spun out from the University of Edinburgh in 2020. ...